Friday, August 29, 2008 - 3:45PM EST

Radiation Therapy

1. Outcome of hyperfractionated radiotherapy in chemotherapy-resistant non-Hodgkin's lymphoma.

Author
Martens C; Hodgson DC; Wells WA; Sun A; Bezjak A; Pintilie M; Crump M; Gospodarowicz MK; Tsang R; Martens C; Hodgson DC; Wells WA; Sun A; Bezjak A; Pintilie M; Crump M; Gospodarowicz MK; Tsang R;
Institution
Department of Radiation Oncology, Princess Margaret Hospital, University Health Network, Toronto, ON, Canada.
Journal
Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):1183-7. Epub 2006 Jan 10.
Abstract URL
Click here to view abstract

2. Retreatment with yttrium-90 ibritumomab tiuxetan in patients with B-cell non-Hodgkin's lymphoma.

Author
Shah J; Wang W; Harrough VD; Saville W; Meredith R; Shen S; Mueh J; Lister J; Jasthy S; Maggass G; McKay C; Krumdieck R; Tharp M; Winter C; Gregory S; Buchholz W; Awasthi S; Jacobs S; Chung H; Egner J; Lobuglio AF; Forero A;
Institution
Department of Medicine, Division of Hematology/Oncology, University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL, USA.
Journal
Leuk Lymphoma. 2007 Sep;48(9):1736-44.
Abstract URL
Click here to view abstract

3. Safety and efficacy of external beam radiation therapy for non-Hodgkin lymphoma in patients with prior 90Y-ibritumomab tiuxetan radioimmunotherapy.

Author
Justice TE; Martenson JA; Wiseman GA; Witzig TE;
Institution
Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA.
Journal
Cancer. 2006 Jul 15;107(2):433-8.
Abstract URL
Click here to view abstract

4. Dexa-BEAM as salvage therapy in patients with primary refractory aggressive non-Hodgkin lymphoma.

Author
Atta J; Chow KU; Weidmann E; Mitrou PS; Hoelzer D; Martin H;
Institution
Department of Hematology, J. W. Goethe-University Hospital, Frankfurt, Germany. atta@em.uni-frankfurt.de
Journal
Leuk Lymphoma. 2007 Feb;48(2):349-56.
Abstract URL
Click here to view abstract

5. Therapeutic radiation for lymphoma: risk of malignant mesothelioma.

Author
Teta MJ; Lau E; Sceurman BK; Wagner ME;
Institution
Exponent, Inc., Health Sciences Practice, New York, New York, USA. jteta@exponent.com
Journal
Cancer. 2007 Apr 1;109(7):1432-8.
Abstract URL
Click here to view abstract